

8EHQ-11-18425

337708

SANITIZED COPY

RECEIVED  
OPPT CBIC

2011 AUG 25 AM 6:07

August 17, 2011

United States Environmental Protection Agency - East  
Attention: TSCA Section 8(e)  
Room 6428 1201 Constitution Avenue, NW  
Washington, DC 20004



**Subject: Notice in Accordance with Section 8(e): Results of a one-hour inhalation toxicity test with CASRN 1184-76-5; diiododifluoromethane**

Dear Sir or Madam,

The purpose of this letter is to inform the EPA of results from a one-hour inhalation toxicity study in rats conducted on CASRN 1184-76-5, diiododifluoromethane, by [REDACTED]. In this study, all animals showed signs of severe respiratory distress and died approximately 50 minutes into the exposure.

The final report will be forwarded upon receipt.

Company identity is considered confidential business information (CBI). CBI substantiation is enclosed.

For questions, please contact [REDACTED]

Sincerely,

[REDACTED]

[REDACTED]



Company Sanitized

Company Sanitized

SANITIZED

CBI Substantiation Questions

1. Is your company asserting this confidential business information (CBI) claim on its own behalf? If the answer is no, please provide company name, address and telephone number of entity asserting claim.

- [REDACTED] is asserting this confidential business information (CBI) claim on its own behalf.

2. For what period do you assert your claim(s) of confidentiality? If the claim is to extend until a certain event or point in time, please indicate that event or time period. Explain why such information should remain confidential until such point.

- The period of time for confidentiality should be indefinite because [REDACTED] plans to [REDACTED]

3. Has the information that you are claiming as confidential been disclosed to any other governmental agency or to this Agency at any other time? Identify the Agency to which the information was disclosed and provide the date and circumstances of the same. Was the disclosure accompanied by a claim of confidentiality? If yes, attach a copy of said document reflecting the confidentiality agreement.

- The information claimed as confidential has not been previously disclosed to any governmental agency.

4. Briefly describe any physical or procedural restrictions within your company relating to the use and storage of the information you are claiming CBI.

- The measures taken to prevent undesired disclosure include standard security procedures, [REDACTED]

5. If anyone outside your company has access to any of the information claimed CBI, are they restricted by confidentiality agreement(s). If so, explain the content of the agreement(s).

- No one outside [REDACTED] has access to the information claimed CBI.

6. Does the information claimed as confidential appear or is it referred to in any of the following:

SANITIZED

- The information claimed as confidential does not appear in any advertising or promotional materials, material safety data sheets or technical datasheets, professional or trade publications, or any other media publications available to the public.
7. Has EPA, another federal agency, or court made any confidentiality determination regarding information associated with this substance? If so, provide copies of such determinations.
- No previous confidentiality determinations by EPA or any other federal agency have been made on this substance.
8. Describe the substantial harmful effects that would result to your competitive position if the CBI information is made available to the public? In your answer, explain the causal relationship between disclosure and any resulting substantial harmful effects. Consider in your answer such constraints as capital and marketing cost, specialized technical expertise, or unusual processes and your competitors' access to your customers. Address each piece of information claimed CBI separately.
- [REDACTED]

[REDACTED] is only claiming its identity as the submitter as confidential, not the chemical identity of the substance.

[REDACTED]
9. Has the substance been patented in the U.S. or elsewhere? Is a patent for the substance currently pending?
- The substance does not have any existing or pending patents.
10. Is this substance/product commercially available and if so, for how long has it been available on the commercial market?
- To 

[REDACTED]

 knowledge, the substance is not available commercially in the U.S.
    - a. If on the commercial market, are your competitors aware that the substance is commercially available in the U.S.?

SANITIZED

- Not Applicable.

b. If not already commercially available, describe what stage of research and development (R&D) the substance is in, and estimate how soon a market will be established.

- Not Applicable.

c. What is the substance used for and what type of product(s) does it appear in.

- 

[REDACTED]

11. Describe whether a competitor could employ reverse engineering to identically recreate the substance?

- Not Applicable. [REDACTED] is only claiming its identity as the submitter as confidential, not the chemical identity of the substance.

12. Do you assert that disclosure of this information you are claiming CBI would reveal:

a. confidential processes used in manufacturing the substance;

- No.

[REDACTED]

b. if a mixture, the actual portions of the substance in the mixture; or

- No. [REDACTED] is only claiming its identity as the submitter as confidential, not the chemical identity of the substance. Additionally, the 8(e) notice discloses the identity of the substance which is not a mixture.

c. information unrelated to the effects of the substance on human health or the environment?

- Yes. [REDACTED] is claiming its identity as the submitter as confidential.

If your answer to any of the above questions is yes, explain how such information would be revealed.

- [REDACTED] identity as the submitter would be revealed if not redacted.

SANITIZED

13. Provide the Chemical Abstract Service Registry Number for the product, if known. Is your company applying for a CAS number now or in the near future? If you have applied for a CAS number, include a copy of the contract with CAS.

- 1184-76-5

14. Is the substance or any information claimed CBI the subject of FIFRA regulation or reporting? If so, explain.

- The substance and information claimed CBI are not the subject of FIFRA regulation or reporting.

